Lonza and Qurient Co. Ltd. have announced a major strategic partnership that marks a significant leap forward in the evolution of oncology treatments. The two companies have entered into an exclusive licensing agreement that grants Lonza the right to integrate Qurient’s advanced cyclin-dependent kinase 7 (CDK7) inhibitors into its portfolio of next-generation antibody-drug conjugates (ADCs).
ADCs have long been heralded as the “magic bullets” of the pharmaceutical industry, designed to navigate the bloodstream to deliver highly potent cytotoxic drugs directly to tumor cells while sparing healthy tissue. By joining forces, Lonza and Qurient are moving toward a more sophisticated iteration of this technology: dual-payload ADCs.
Dual-payload ADCs represent a significant departure from conventional single-agent therapies. By arming a single antibody with two distinct cytotoxic agents, developers can hit cancer cells through multiple biological pathways simultaneously. This multi-pronged approach is intended to increase treatment efficacy and potentially reduce the likelihood of tumor resistance.
The centerpiece of this collaboration is the launch of Lonza’s new “SYN-duo CC” format. This platform combines a topoisomerase I inhibitor—a widely used class of anticancer agent—with Qurient’s highly selective, clinical-stage CDK7 inhibitor. The combination is engineered to allow the CDK7 inhibitor to sensitize the tumor, thereby enhancing the overall potency of the topoisomerase I inhibitor.
“This agreement adds a differentiated CDK7 inhibitor payload technology to Lonza’s ADC toolbox and further strengthens our ability to support customers from early technology evaluation through development, manufacturing and commercialization,” said Christian Seufert, Head of Advanced Synthesis at Lonza.
The agreement is broad in scope, providing Lonza the flexibility to go beyond the initial SYN-duo CC format. Lonza will be able to leverage its proprietary ADC platform to explore other dual-payload configurations, pairing Qurient’s inhibitors with various other drug technologies. This modularity is expected to provide pharmaceutical developers with a versatile “menu” of options as they tailor treatments to specific tumor types and complex patient profiles.
Kiyean Nam, CEO of Qurient, highlighted the strategic importance of the partnership, noting that the collaboration marries Qurient’s deep expertise in CDK7 inhibition with Lonza’s manufacturing and development scale. “We believe CDK7 inhibition offers significant potential as part of the next generation of dual-payload ADCs,” Nam said.
This announcement comes during a period of rapid expansion for Lonza, which continues to aggressively pursue innovation in the biopharmaceutical sector. Just last week, the company entered into a high-profile collaboration with biotechnology startup Onava to integrate artificial intelligence into the discovery of biologic drugs. By focusing on both AI-driven discovery and next-generation delivery platforms like ADCs, Lonza is positioning itself at the forefront of the precision medicine revolution.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
